Joe Newell - Nov 15, 2021 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
Chief Operations Officer
Signature
/s/ David Tucker, Attorney-in-Fact for Joe Newell
Stock symbol
ATRA
Transactions as of
Nov 15, 2021
Transactions value $
-$81,479
Form type
4
Date filed
11/17/2021, 03:15 PM
Previous filing
Sep 24, 2021
Next filing
Nov 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Options Exercise $42.5K +3.5K +2.92% $12.15* 123K Nov 15, 2021 Direct F1
transaction ATRA Common Stock Sale -$124K -7K -5.67% $17.71* 116K Nov 15, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATRA Employee Stock Option (Right to Buy) Options Exercise $0 -2.79K -8.01% $0.00 32.1K Nov 15, 2021 Common Stock 2.79K $12.15 Direct F1, F3
transaction ATRA Employee Stock Option (Right to Buy) Options Exercise $0 -708 -6.66% $0.00 9.92K Nov 15, 2021 Common Stock 708 $12.15 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020.
F2 The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.62 to $17.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service.